Guard Therapeutics International AB (publ)

OM:GUARD Stock Report

Market Cap: SEK 258.2m

Guard Therapeutics International Management

Management criteria checks 1/4

Guard Therapeutics International's CEO is Tobias Agervald, appointed in Jan 2019, has a tenure of 5.83 years. directly owns 0.2% of the company’s shares, worth SEK527.95K. The average tenure of the management team and the board of directors is 4.2 years and 2.7 years respectively.

Key information

Tobias Agervald

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.8yrs
CEO ownership0.2%
Management average tenure4.2yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Nov 19
We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18
Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04
Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Sep 20
Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

Apr 06
Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Sep 09
We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Feb 19
Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Aug 17
We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Apr 19
Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Jan 04
Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

CEO Compensation Analysis

How has Tobias Agervald's remuneration changed compared to Guard Therapeutics International's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 87m

Jun 30 2024n/an/a

-SEK 79m

Mar 31 2024n/an/a

-SEK 88m

Dec 31 2023n/an/a

-SEK 113m

Sep 30 2023n/an/a

-SEK 137m

Jun 30 2023n/an/a

-SEK 146m

Mar 31 2023n/an/a

-SEK 134m

Dec 31 2022SEK 5mSEK 2m

-SEK 113m

Sep 30 2022n/an/a

-SEK 95m

Jun 30 2022n/an/a

-SEK 97m

Mar 31 2022n/an/a

-SEK 88m

Dec 31 2021SEK 4mSEK 2m

-SEK 82m

Sep 30 2021n/an/a

-SEK 69m

Jun 30 2021n/an/a

-SEK 47m

Mar 31 2021n/an/a

-SEK 44m

Dec 31 2020SEK 3mSEK 1m

-SEK 40m

Sep 30 2020n/an/a

-SEK 43m

Jun 30 2020n/an/a

-SEK 39m

Mar 31 2020n/an/a

-SEK 41m

Dec 31 2019SEK 4mSEK 1m

-SEK 45m

Compensation vs Market: Insufficient data to establish whether Tobias's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Tobias's compensation has increased whilst the company is unprofitable.

CEO

Tobias Agervald (48 yo)

5.8yrs

Tenure

SEK 5,230,000

Compensation

Mr. Tobias Larsson Agervald has been Chief Executive Officer at Guard Therapeutics International AB (publ) (formerly known as A1M Pharma AB (publ))since January 15, 2019 and served as its Chief Medical Off...

Leadership Team

NamePositionTenureCompensationOwnership
Tobias Agervald
Chief Executive Officer5.8yrsSEK 5.23m0.20%
SEK 528.0k
Karin Botha
Chief Financial Officer4.2yrsno data0.023%
SEK 59.7k
Magnus Gram
C.S.O5.4yrsno datano data
Peter Gilmour
Head of Preclinical Science4.3yrsno datano data
Sara Thuresson
Head of Clinical Operations3.5yrsno data0.016%
SEK 40.9k
Michael Reusch
Chief Medical Officer2.8yrsno datano data
Torbjorn Larsson
Head of Chemistry2.5yrsno data0.0016%
SEK 4.2k

4.2yrs

Average Tenure

51yo

Average Age

Experienced Management: GUARD's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Johan Bygge
Independent Chairman of the board3.5yrsSEK 271.00k0.051%
SEK 132.0k
Khatereh Ahmadi
Non-Executive Directorless than a yearno datano data
Michael Brownstein
Member of Scientific Boardno datano datano data
Goran Forsberg
Non-Executive Independent Director5.5yrsSEK 162.00k0.011%
SEK 28.7k
Fredrik Lehmann
Non-Executive Independent Director1.9yrsSEK 7.00kno data
Gunvor Ordeberg
Member of Scientific Boardno datano datano data
Anthony Kettle
Member of Scientific Boardno datano datano data
Christopher Redman
Member of Scientific Boardno datano datano data
Henning Schneider
Member of Scientific Boardno datano datano data
Johannes Hulthe
Non-Executive Independent Director5.5yrsSEK 162.00k0.049%
SEK 126.0k
Hege Hellstrom
Non-Executive Directorless than a yearno datano data
József Balla
Member of Scientific Boardno datano datano data

2.7yrs

Average Tenure

59yo

Average Age

Experienced Board: GUARD's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.